NorthWest Biotherapeutics Inc (NWBO)

[john1045]

In yesterday's presentation on Slide 2, she highlighted a a number of milestones with DCVax-L for GBM and NWBO reaching first interim analysis in the by trial end of Q2 or Q3 2013. In Slide 14, highlights 6-month of progression free survival to meet primary endpoint of trial-only 1/3 as long as extension of PFS seen in Phase I/II trials.

The DCVax-Direct Phase I/II "All Comers" trial is progressing for patients with colon, liver, pancreas, melanoma & misc.with key endpoints Safety & Tumor Regression. If NWBO shows striking results from terminal patients with inoperable tumors they hit the pall out of the park immediately as they expect to have results in this trial in 1H of 2013.